

Nicoletta Colombo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8246682/publications.pdf>

Version: 2024-02-01

206
papers

18,214
citations

23567

58
h-index

14759

127
g-index

207
all docs

207
docs citations

207
times ranked

13494
citing authors

#	ARTICLE	IF	CITATIONS
1	ADAGIO: a phase IIb international study of the Wee1 inhibitor adavosertib in women with recurrent or persistent uterine serous carcinoma. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 89-92.	2.5	13
2	Clear cell carcinoma of the endometrium. <i>Gynecologic Oncology</i> , 2022, 164, 658-666.	1.4	23
3	Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent) Tj ETQq1 1 0.784314 rgBT /Overlock 505-513.	1.4	35
4	Efficacy and safety of olaparib according to age in BRCA1/2-mutated patients with recurrent platinum-sensitive ovarian cancer: Analysis of the phase III SOLO2/ENGOT-Ov21 study. <i>Gynecologic Oncology</i> , 2022, 165, 40-48.	1.4	10
5	Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 437-448.	27.0	375
6	Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial. <i>Gynecologic Oncology</i> , 2022, 164, 254-264.	1.4	51
7	The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples. <i>Nature Communications</i> , 2022, 13, 449.	12.8	21
8	Survival with Cemiplimab in Recurrent Cervical Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 544-555.	27.0	182
9	Tumor BRCA Testing in Epithelial Ovarian Cancers: Past and Futureâ€™Five-Yearsâ€™™ Single-Institution Experience of 762 Consecutive Patients. <i>Cancers</i> , 2022, 14, 1638.	3.7	3
10	Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients. <i>Cancers</i> , 2022, 14, 1849.	3.7	3
11	Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 465-478.	10.7	70
12	Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies. <i>ESMO Open</i> , 2022, 7, 100459.	4.5	26
13	CT-Based Radiomics and Deep Learning for BRCA Mutation and Progression-Free Survival Prediction in Ovarian Cancer Using a Multicentric Dataset. <i>Cancers</i> , 2022, 14, 2739.	3.7	19
14	AGO-OVAR 28/ENGOT-ov57: Niraparib versus niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancerâ€™A multicenter, randomized, phase III trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS5612-TPS5612.	1.6	5
15	ENGOT-ov65/KEYNOTE-B96: Phase 3, randomized, double-blind study of pembrolizumab versus placebo plus paclitaxel with optional bevacizumab for platinum-resistant recurrent ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS5617-TPS5617.	1.6	0
16	Efficacy of next line of therapy after treatment with lenvatinib (LEN) in combination with pembrolizumab (pembro) versus treatment of physicianâ€™s choice (TPC) in patients (pts) with advanced endometrial cancer (aEC): Exploratory analysis of Study 309/KEYNOTE-775.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5587-5587.	1.6	1
17	Hematological disorders after salvage <sc>PARPi</sc> treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes. <i>International Journal of Cancer</i> , 2022, 151, 1791-1803.	5.1	7
18	Evaluation of perioperative management of advanced ovarian (tubal/peritoneal) cancer patients: a survey from MITO-MaNGO Groups. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	2.2	1

#	ARTICLE	IF	CITATIONS
19	Overall survival data from a 3-arm, randomized, open-label, phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA5503-LBA5503.	1.6	4
20	Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers. <i>Gynecologic Oncology</i> , 2021, 160, 64-70.	1.4	6
21	Clinical presentation, diagnosis and management of therapy-related hematological disorders in women with epithelial ovarian cancer treated with chemotherapy and poly(ADP-ribose) polymerase inhibitors: A single-center experience. <i>International Journal of Cancer</i> , 2021, 148, 170-177.	5.1	9
22	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. <i>Radiotherapy and Oncology</i> , 2021, 154, 327-353.	0.6	96
23	Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2021, 22, 267-276.	10.7	79
24	ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 153-190.	2.8	99
25	Role of inhibin B in detecting recurrence of granulosa cell tumors of the ovary in postmenopausal patients. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 893-898.	2.5	9
26	Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 875-882.	2.5	19
27	ENGOT-ov60/GOG3052/RAMP 201: A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS5603-TPS5603.	1.6	4
28	Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2021, 22, 632-642.	10.7	40
29	Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2021, 22, 620-631.	10.7	215
30	Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 949-958.	2.5	7
31	Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39). <i>Journal of Clinical Oncology</i> , 2021, 39, 1842-1855.	1.6	183
32	Uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2021, 162, 226-234.	1.4	58
33	Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial. <i>Gynecologic Oncology</i> , 2021, 163, 41-49.	1.4	17
34	Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1348-1355.	2.5	3
35	Pre-transplant minimal residual disease assessment and transplant-related factors predict the outcome of acute myeloid leukemia patients undergoing allogeneic stem cell transplantation. <i>European Journal of Haematology</i> , 2021, 107, 573-582.	2.2	7
36	ORZORA: Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status. <i>Gynecologic Oncology</i> , 2021, 162, S29.	1.4	4

#	ARTICLE	IF	CITATIONS
37	Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL). <i>Gynecologic Oncology</i> , 2021, 163, 237-245.	1.4	30
38	Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 1856-1867.	27.0	440
39	Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety. <i>Cancer Medicine</i> , 2021, 10, 7162-7173.	2.8	4
40	Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1275-1289.	10.7	118
41	Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer. <i>European Journal of Cancer</i> , 2021, 157, 415-423.	2.8	18
42	Concordance Between Tumor and Germline <i><i>BRCA</i></i> Status in High-Grade Ovarian Carcinoma Patients in the Phase III PAOLA-1/ENGOT-ov25 Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 917-923.	6.3	26
43	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 12-39.	2.5	859
44	Fludarabine, High-Dose Cytarabine and Idarubicin-Based Induction May Overcome the Negative Prognostic Impact of FLT3-ITD in NPM1 Mutated AML, Irrespectively of FLT3-ITD Allelic Burden. <i>Cancers</i> , 2021, 13, 34.	3.7	10
45	Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician's choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NtCHE trial (MITO 33). <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1369-1373.	2.5	12
46	Preexisting <i><i>TP53</i></i> -Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. <i>JAMA Oncology</i> , 2021, 7, 1772.	7.1	44
47	Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1721-1731.	10.7	172
48	L1CAM promotes ovarian cancer stemness and tumor initiation via FGFR1/SRC/STAT3 signaling. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 319.	8.6	20
49	Evaluation of Angiogenesis-Related Genes as Prognostic Biomarkers of Bevacizumab Treated Ovarian Cancer Patients: Results from the Phase IV MITO16A/ManGO OV-2 Translational Study. <i>Cancers</i> , 2021, 13, 5152.	3.7	7
50	A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 617-622.	2.5	21
51	Maintenance Treatment of Newly Diagnosed Advanced Ovarian Cancer: Time for a Paradigm Shift?. <i>Cancers</i> , 2021, 13, 5756.	3.7	11
52	Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis. <i>Journal of Clinical Pathology</i> , 2020, 73, 168-171.	2.0	14
53	Final results from GCIG/ENGOT/AGO- <i>OVAR</i> 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. <i>International Journal of Cancer</i> , 2020, 146, 439-448.	5.1	40
54	A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups. <i>Oncologist</i> , 2020, 25, e311-e320.	3.7	56

#	ARTICLE	IF	CITATIONS
55	Pre-operative evaluation of epithelial ovarian cancer patients: Role of whole body diffusion weighted imaging MR and CT scans in the selection of patients suitable for primary debulking surgery. A single-centre study. <i>European Journal of Radiology</i> , 2020, 123, 108786.	2.6	31
56	Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Società Italiana Ginecologica Oncologica). <i>Journal of Gynecological Oncology</i> , 2020, 10, 10.	2.8	21
57	Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy. <i>European Journal of Cancer</i> , 2020, 139, 59-67.	2.8	12
58	DNA methylation signatures to predict the cervicovaginal microbiome status. <i>Clinical Epigenetics</i> , 2020, 12, 180.	4.1	3
59	Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3528-3537.	1.6	64
60	First-Line Treatment with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research. <i>Cancer Management and Research</i> , 2020, Volume 12, 5479-5489.	1.9	3
61	Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer. <i>Gynecologic Oncology</i> , 2020, 159, 142-149.	1.4	30
62	A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer. <i>Genome Medicine</i> , 2020, 12, 94.	8.2	11
63	ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies. <i>ESMO Open</i> , 2020, 5, e000827.	4.5	18
64	Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3494-3505.	1.6	28
65	Anthracycline-based and gemcitabine-based chemotherapy in the adjuvant setting for stage I uterine leiomyosarcoma: a retrospective analysis at two reference centers. <i>Clinical Sarcoma Research</i> , 2020, 10, 17.	2.3	5
66	The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma. <i>Gynecologic Oncology</i> , 2020, 159, 101-111.	1.4	14
67	Implementing clinical practice guidelines: time to assess it. <i>ESMO Open</i> , 2020, 5, e001130.	4.5	0
68	Results of the interprofessional and interdisciplinary Berlin round table on patient-reported outcomes, quality of life, and treatment expectations of patients with gynecological cancer under maintenance treatment. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1603-1607.	2.5	4
69	Prognostic relevance of a blastic plasmacytoid dendritic cell neoplasm-like immunophenotype in cytogenetically normal acute myeloid leukemia patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1695-1701.	1.3	4
70	Aromatase Inhibitors as Adjuvant Treatment for ER/PgR Positive Stage I Endometrial Carcinoma: A Retrospective Cohort Study. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2227.	4.1	9
71	Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service. <i>Clinical Therapeutics</i> , 2020, 42, 1192-1209.e12.	2.5	9
72	Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1164-1174.	1.6	194

#	ARTICLE	IF	CITATIONS
73	Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 710-722.	10.7	70
74	Intensity modulated radiation therapy boost in locally-advanced cervical cancer in the absence of brachytherapy. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 607-612.	2.5	8
75	ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS6096-TPS6096.	1.6	28
76	Outcome according to residual disease (surgeon's report vs pre-chemotherapy imaging) in patients with bevacizumab-treated ovarian cancer: Analysis of the ROSiA study. <i>Journal of Surgical Oncology</i> , 2019, 120, 786-793.	1.7	4
77	Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study. <i>Lancet Oncology</i> , The, 2019, 20, 1171-1182.	10.7	108
78	Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with <i>NPM1</i> mutation: from definition of molecular relapse to MRD-driven salvage approach. <i>British Journal of Haematology</i> , 2019, 186, e223-e225.	2.5	9
79	Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status. <i>Cancer Treatment Reviews</i> , 2019, 80, 101909.	7.7	63
80	A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2019, 86, 106223.	0.8	7
81	BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories. <i>Diagnostics</i> , 2019, 9, 146.	2.6	3
82	Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy. <i>Cancers</i> , 2019, 11, 1641.	3.7	22
83	Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer. <i>British Journal of Cancer</i> , 2019, 121, 744-750.	6.4	10
84	Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1141-1147.	2.5	11
85	Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 140, 67-72.	4.4	51
86	Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 862-876.	10.7	68
87	Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2416-2428.	27.0	1,176
88	Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information. <i>British Journal of Haematology</i> , 2019, 184, 457-460.	2.5	13
89	Olaparib monotherapy versus (vs) chemotherapy for germline BRCA-mutated (gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase III SOLO3 trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5506-5506.	1.6	14
90	Epigenome-based cancer risk prediction: rationale, opportunities and challenges. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 292-309.	27.6	129

#	ARTICLE	IF	CITATIONS
91	Stereotactic Body Radiation Therapy for Oligometastatic Ovarian Cancer: A Step Toward a Drug Holiday. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 650-660.	0.8	65
92	FORWARD I: a Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. <i>Future Oncology</i> , 2018, 14, 1669-1678.	2.4	55
93	CD73 Regulates Stemness and Epithelial-Mesenchymal Transition in Ovarian Cancer-Initiating Cells. <i>Stem Cell Reports</i> , 2018, 10, 1412-1425.	4.8	94
94	A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of <i>npm1</i> -mutated acute myeloid leukemia patients with worse prognosis. <i>American Journal of Hematology</i> , 2018, 93, E33-E35.	4.1	16
95	Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents. <i>Haematologica</i> , 2018, 103, 80-90.	3.5	48
96	Evaluation of a Streamlined Oncologist-Led <i>BRCA</i> Mutation Testing and Counseling Model for Patients With Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1300-1307.	1.6	76
97	Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2495-2505.	27.0	1,854
98	Recurrent ovarian cancer 8 months after induction and bevacizumab consolidation: rationale for using trabectedin+Âpegylated liposomal doxorubicin in second line. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 13-17.	2.4	3
99	A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma. <i>British Journal of Cancer</i> , 2018, 119, 565-571.	6.4	15
100	Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months. <i>European Radiology</i> , 2018, 28, 4849-4859.	4.5	100
101	Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab. <i>International Journal of Cancer</i> , 2018, 143, 2187-2199.	5.1	8
102	Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: The randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5506-5506.	1.6	55
103	Multidisciplinary approach in the management of advanced ovarian cancer patients: A personalized approach. Results from a specialized ovarian cancer unit. <i>Gynecologic Oncology</i> , 2017, 144, 468-473.	1.4	28
104	Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective. <i>Journal of Clinical Oncology</i> , 2017, 35, 587-590.	1.6	38
105	Combining flow cytometry and <i>WT1</i> assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia. <i>Haematologica</i> , 2017, 102, e348-e351.	3.5	26
106	ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. <i>European Journal of Cancer</i> , 2017, 70, 111-121.	2.8	70
107	Feasibility of Transabdominal Cardiophrenic Lymphnode Dissection in Advanced Ovarian Cancer: Initial Experience at a Tertiary Center. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1268-1273.	2.5	22
108	Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial. <i>Gynecologic Oncology</i> , 2017, 144, 256-259.	1.4	38

#	ARTICLE	IF	CITATIONS
109	Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet</i> , The, 2017, 390, 1949-1961.	13.7	1,261
110	Impact of Recurrence of Ovarian Cancer on Quality of Life and Outlook for the Future. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1134-1140.	2.5	65
111	Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1274-1284.	10.7	1,376
112	Restoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: Myth or reality?. <i>Cancer</i> , 2017, 123, 3450-3459.	4.1	48
113	Clinical benefit and risk of death with endocrine therapy in ovarian cancer: A comprehensive review and meta-analysis. <i>Gynecologic Oncology</i> , 2017, 146, 504-513.	1.4	39
114	When nonplatinum is the answer: the role of trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. <i>Future Oncology</i> , 2017, 13, 23-29.	2.4	19
115	Ovarian Sex Cord Tumors. , 2017, , 261-279.		0
116	Risk-reducing Salpingo-oophorectomy in Women at Higher Risk of Ovarian and Breast Cancer: A Single Institution Prospective Series. <i>Anticancer Research</i> , 2017, 37, 5241-5248.	1.1	11
117	Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients. <i>Future Oncology</i> , 2016, 12, 2071-2075.	2.4	21
118	High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients. <i>American Journal of Hematology</i> , 2016, 91, 755-762.	4.1	18
119	Robotic Versus Open Radical Hysterectomy in Women With Locally Advanced Cervical Cancer After Neoadjuvant Chemotherapy: A Single-institution Experience of Surgical and Oncologic Outcomes. <i>Journal of Minimally Invasive Gynecology</i> , 2016, 23, 909-916.	0.6	11
120	Ultrasonographic diagnosis and longitudinal follow-up of recurrences after conservative surgery for borderline ovarian tumors. <i>American Journal of Obstetrics and Gynecology</i> , 2016, 215, 756.e1-756.e9.	1.3	17
121	Long-term results of fertility-sparing treatment compared with standard radical surgery for early-stage epithelial ovarian cancer. <i>British Journal of Cancer</i> , 2016, 115, 641-648.	6.4	50
122	Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. <i>European Journal of Cancer</i> , 2016, 69, 127-134.	2.8	49
123	Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 11-19.	2.4	6
124	Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENLOPE). <i>Journal of Clinical Oncology</i> , 2016, 34, 2516-2525.	1.6	60
125	Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 78-89.	10.7	205
126	BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study. <i>Gynecologic Oncology</i> , 2016, 140, 443-449.	1.4	47

#	ARTICLE	IF	CITATIONS
127	Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1242-1246.	2.0	41
128	Fertility-Sparing Options in Young Women with Cervical Cancer. <i>Current Treatment Options in Oncology</i> , 2016, 17, 5.	3.0	19
129	Special issues in fertility preservation for gynecologic malignancies. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 206-219.	4.4	51
130	Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 97, 335-348.	4.4	22
131	SIRT6 Inhibition As a Novel Approach for Treating Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 5222-5222.	1.4	0
132	European Network of Gynaecological Oncological Trial Groupsâ€™ Requirements for Trials Between Academic Groups and Industry Partnersâ€™ First Update 2015. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1328-1330.	2.5	22
133	Medical treatment of early stage and rare histological variants of epithelial ovarian cancer. <i>Ecanermedalscience</i> , 2015, 9, 584.	1.1	7
134	Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma. <i>BioMed Research International</i> , 2015, 2015, 1-8.	1.9	13
135	Progression-free survival by local investigator versus independent central review: Comparative analysis of the AGO-OVAR16 Trial. <i>Gynecologic Oncology</i> , 2015, 136, 37-42.	1.4	29
136	Long-term follow-up of patients with an isolated ovarian recurrence after conservative treatment of epithelial ovarian cancer: review of the results of an international multicenter study comprising 545 patients. <i>Fertility and Sterility</i> , 2015, 104, 1319-1324.	1.0	64
137	Neoadjuvant chemotherapy in cervical cancer: an update. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1171-1181.	2.4	34
138	Is Endometrial Cancer Risk Reduced by Oral Bisphosphonate Use?. <i>Journal of Clinical Oncology</i> , 2015, 33, 3670-3670.	1.6	1
139	Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes. <i>Leukemia Research</i> , 2015, 39, 866-873.	0.8	11
140	Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 87-97.	10.7	491
141	A Novel Synthetic Lethal Approach Targeting SIRT6 in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 1375-1375.	1.4	1
142	High Predictive Value of Pre Transplant Minimal Residual Disease Assessment By Combining WT1 Expression and Flow Cytometry in Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 2029-2029.	1.4	1
143	Optimising the treatment of the partially platinum-sensitive relapsed ovarian cancer patient. <i>European Journal of Cancer</i> , Supplement, 2014, 12, 7-12.	2.2	13
144	Adult granulosa cell tumours of the ovary. <i>Current Opinion in Oncology</i> , 2014, 26, 536-541.	2.4	19

#	ARTICLE	IF	CITATIONS
145	Gynecologic Cancer InterGroup (GCIg) Consensus Review for Ovarian Sex Cord Stromal Tumors. <i>International Journal of Gynecological Cancer</i> , 2014, 24, S42-S47.	2.5	74
146	Treatment Options for Pregnant Women With Ovarian Tumors. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 967-972.	2.5	18
147	Adjuvant chemotherapy in stage II uterine leiomyosarcoma: A multicentric retrospective study of 140 patients. <i>Gynecologic Oncology</i> , 2014, 133, 531-536.	1.4	34
148	Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: Results of a randomized, double-blind, phase 2, parallel-arm study. <i>Cancer</i> , 2014, 120, 335-343.	4.1	49
149	Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities. <i>Cancer Treatment Reviews</i> , 2014, 40, 648-655.	7.7	101
150	Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin. <i>Cancer Treatment Reviews</i> , 2014, 40, 366-375.	7.7	58
151	Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 320-326.	1.6	99
152	Fragment-based hit discovery and structure-based optimization of aminotriazoloquinazolines as novel Hsp90 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 4135-4150.	3.0	34
153	Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 3374-3382.	1.6	302
154	Independent review of AGO-OVAR 12, a GCIg/ENGOT-Intergroup phase III trial of nintedanib (N) in first-line therapy for ovarian cancer (OC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 5556-5556.	1.6	2
155	Genome-wide association study (GWAS) of pazopanib efficacy and safety in patients with ovarian cancer who have not progressed following first-line standard therapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5574-5574.	1.6	1
156	Are monoclonal antibodies a safe treatment for cancer during pregnancy?. <i>Immunotherapy</i> , 2013, 5, 733-741.	2.0	33
157	Integrating post induction WT1 quantification and flow-cytometry results improves minimal residual disease stratification in acute myeloid leukemia. <i>Leukemia Research</i> , 2013, 37, 1606-1611.	0.8	36
158	Discovery of NMS-E973 as novel, selective and potent inhibitor of heat shock protein 90 (Hsp90). <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 7047-7063.	3.0	23
159	A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma. <i>Gynecologic Oncology</i> , 2013, 130, 25-30.	1.4	79
160	Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression. <i>British Journal of Haematology</i> , 2013, 160, 503-509.	2.5	64
161	Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials. <i>Medical Oncology</i> , 2013, 30, 435.	2.5	30
162	Reply to M.L. Friedlander et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 2363-2363.	1.6	2

#	ARTICLE	IF	CITATIONS
163	Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICOâ€”The MIMOSA Study. <i>Journal of Clinical Oncology</i> , 2013, 31, 1554-1561.	1.6	126
164	External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma. <i>Cancer</i> , 2013, 119, 1816-1822.	4.1	54
165	Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. <i>British Journal of Cancer</i> , 2013, 108, 1021-1026.	6.4	118
166	Optimizing treatment of the partially platinum-sensitive ovarian cancer patient. <i>Future Oncology</i> , 2013, 9, 19-23.	2.4	18
167	Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): Results of an international Intergroup trial (AGO-OVAR16).. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA5503-LBA5503.	1.6	35
168	Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 3841-3847.	1.6	110
169	Nucleophosmin gene-based monitoring inde novocytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression. <i>Leukemia and Lymphoma</i> , 2012, 53, 2214-2217.	1.3	9
170	Molecular Recognition of T:G Mismatched Base Pairs in DNA as Studied by Electrospray Ionization Mass Spectrometry. <i>ChemMedChem</i> , 2012, 7, 1112-1122.	3.2	5
171	A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. <i>Gynecologic Oncology</i> , 2012, 125, 42-47.	1.4	88
172	Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 5001-5001.	1.6	50
173	Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCIG and EORTC-GCC study.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA5000-LBA5000.	1.6	7
174	Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A GCIG and EORTC-GCC study.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA5000-LBA5000.	1.6	12
175	The European Society of Gynaecological Oncology: Update on Objectives and Educational and Research Activities. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2012, , 335-338.	3.8	0
176	Efficacy of Trabectedin in Platinum-Sensitive-Relapsed Ovarian Cancer: New Data From the Randomized OVA-301 Study. <i>International Journal of Gynecological Cancer</i> , 2011, 21, S12-S16.	2.5	18
177	Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology About the Conservative Management of Ovarian Malignant Tumors. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 951-963.	2.5	85
178	First-Line Therapy in Ovarian Cancer Trials. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 756-762.	2.5	82
179	The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling. <i>EMBO Molecular Medicine</i> , 2011, 3, 480-494.	6.9	67
180	Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2010, 20, 945-952.	2.5	244

#	ARTICLE	IF	CITATIONS
181	Critical Review of Neoadjuvant Chemotherapy Followed by Surgery for Locally Advanced Cervical Cancer. <i>International Journal of Gynecological Cancer</i> , 2010, 20, S47-S48.	2.5	16
182	Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience. <i>Gynecologic Oncology</i> , 2010, 119, 259-264.	1.4	83
183	Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup. <i>Journal of Clinical Oncology</i> , 2009, 27, 1419-1425.	1.6	645
184	Robotic approach for cervical cancer: Comparison with laparotomy A case control study. <i>Gynecologic Oncology</i> , 2009, 115, 60-64.	1.4	121
185	The Differential Role of L1 in Ovarian Carcinoma and Normal Ovarian Surface Epithelium. <i>Cancer Research</i> , 2008, 68, 1110-1118.	0.9	74
186	Management of Ovarian Stromal Cell Tumors. <i>Journal of Clinical Oncology</i> , 2007, 25, 2944-2951.	1.6	282
187	Chemo-conization in early cervical cancer. <i>Gynecologic Oncology</i> , 2007, 107, S125-S126.	1.4	66
188	Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy. <i>Critical Reviews in Oncology/Hematology</i> , 2007, 64, 129-138.	4.4	84
189	Ovarian cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 60, 159-179.	4.4	186
190	A Phase I-II Preoperative Biomarker Trial of Fenretinide in Ascitic Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1914-1919.	2.5	31
191	Randomized Trial of Neoadjuvant Chemotherapy Comparing Paclitaxel, Ifosfamide, and Cisplatin With Ifosfamide and Cisplatin Followed by Radical Surgery in Patients With Locally Advanced Squamous Cell Cervical Carcinoma: The SNAP01 (Studio Neo-Adjuvante Portio) Italian Collaborative Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 4137-4145.	1.6	189
192	Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes Fails. <i>Journal of Clinical Oncology</i> , 2005, 23, 1867-1874.	1.6	163
193	Controversies in chemotherapy - what is standard treatment?. <i>European Journal of Cancer</i> , Supplement, 2003, 1, 107-114.	2.2	0
194	Using the Expected Survival to Explain Differences Between the Results of Randomized Trials: A Case in Advanced Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 1682-1687.	1.6	12
195	International Collaborative Ovarian Neoplasm Trial 1: A Randomized Trial of Adjuvant Chemotherapy in Women With Early-Stage Ovarian Cancer. <i>Journal of the National Cancer Institute</i> , 2003, 95, 125-132.	6.3	256
196	International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. <i>Journal of the National Cancer Institute</i> , 2003, 95, 105-12.	6.3	94
197	Characterization of Small Combinatorial Chemistry Libraries by ¹ H NMR. Quantitation with a Convenient and Novel Internal Standard. <i>ACS Combinatorial Science</i> , 2001, 3, 434-440.	3.3	32
198	Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. <i>Cancer</i> , 1995, 75, 1141-1150.	4.1	122

#	ARTICLE	IF	CITATIONS
199	Effects of granulocyte-monocyte colony-stimulating factor (GM-CSF) on expression of adhesion molecules and production of cytokines in blood monocytes and ovarian cancer-associated macrophages. <i>International Journal of Cancer</i> , 1995, 60, 300-307.	5.1	36
200	Surgical management of malignant ovarian germ-cell tumors: 10 years' experience of 129 patients. <i>Obstetrics and Gynecology</i> , 1995, 86, 367-372.	2.4	97
201	The Effect of Debulking Surgery after Induction Chemotherapy on the Prognosis in Advanced Epithelial Ovarian Cancer. <i>New England Journal of Medicine</i> , 1995, 332, 629-634.	27.0	706
202	Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (hac) vs. cisplatin, adriamycin, cyclophosphamide (pac) in advanced ovarian cancer: long-term results. <i>Cancer Treatment Reviews</i> , 1991, 18, 37-46.	7.7	12
203	The disposition of carboplatin in ovarian cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1988, 22, 263-270.	2.3	43
204	Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: A randomized clinical trial. <i>Cancer Chemotherapy and Pharmacology</i> , 1985, 14, 222-8.	2.3	20
205	Intraperitoneal administration of interferon β in ovarian cancer patients. <i>Cancer</i> , 1985, 56, 294-301.	4.1	61
206	NATURAL KILLER ACTIVITY IN HUMAN OVARIAN TUMORS. , 1982, , 1119-1126.		3